Fate of Multimeric Oligomers, Submicron, and Micron Size Aggregates of Monoclonal Antibodies Upon Subcutaneous Injection in Mice
- 1 April 2016
- journal article
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 105 (5) , 1693-1704
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Developments and Challenges for mAb-Based TherapeuticsAntibodies, 2013
- Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisationAnnals of the Rheumatic Diseases, 2013
- Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics-Based Dosing ParadigmsClinical Pharmacology & Therapeutics, 2012
- Review article: loss of response to anti-TNF treatments in Crohn’s diseaseAlimentary Pharmacology & Therapeutics, 2011
- Therapeutic antibodies for autoimmunity and inflammationNature Reviews Immunology, 2010
- Monoclonal Antibody Pharmacokinetics and PharmacodynamicsClinical Pharmacology & Therapeutics, 2008
- Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritisAnnals of the Rheumatic Diseases, 2007
- Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: A pilot studyClinical Therapeutics, 2003
- Ligand-targeted therapeutics in anticancer therapyNature Reviews Cancer, 2002
- Tumor Detection and Visualization Using Cyanine Fluorochrome-Labeled AntibodiesBiotechnology Progress, 1997